In the majority of adults, the body is able to eliminate the virus without treatment.  Currently, there is no treatment available for acute hepatitis B infection. Symptomatic treatment may be indicated. Early antiviral treatment may only be required in fewer than 1% of patients, whose hepatitis B takes a very aggressive course, such as in cases of fulminant hepatitis. Treatment of chronic infection may be necessary to reduce the risk of cirrhosis and liver cancer.  Chronically infected patients with persistently elevated serum alanine aminotransferase and HBV DNA levels are candidates for therapy.  Treatment lasts from six months to a year, depending on the medication and genotype.  Although none of the available drugs can clear the infection, they can stop the virus from replicating, thus minimizing liver damage. These include antiviral drugs Lamivudine, Adefovir, Tenofovir, Telbivudine and Entecavir, as well as immune system modulators, such as interferon alpha-2a and pegylated interferon-alpha-2a.
Hepatitis B medical therapy
Hepatitis C medical therapy
Hepatitis D medical therapy
Hepatitis E medical therapy
Autoimmune hepatitis medical therapy
Alcoholic hepatitis medical therapy
Hepatitis B secondary prevention
Hepatitis C secondary prevention